Short answer
BioAge Labs, Inc. (BIOA) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). No earnings-period results or financial metrics available in the supplied section.
BioAge Labs, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- No earnings-period results or financial metrics available in the supplied section
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss widened to $26.1M from $21.6M, while R&D rose to $24.4M as BGE-102 trials advanced
- QUELL-CV Phase 2 enrolled its first participant, testing 30 mg, 60 mg, and 90 mg doses in approximately 160 adults
- QUELL-CV topline data expected in the second half of 2026, providing the next major clinical catalyst for BGE-102
- QUELL-DME diabetic macular edema trial planned for mid-2026, with data anticipated in mid-2027 and potential retinal-disease expansion
- Cash, equivalents, and marketable securities totaled approximately $381.3M, projected to fund operations through 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BioAge Labs, Inc. 8-K filings
Get the next BIOA 8-K as it lands
Follow BIOA for push alerts, or ask the research agent what this filing means.